ENLV

Enlivex Ltd

0.1722

Oct 23 • 8:54 AM ET -0.0270 (-13.55%)

Healthcare Biotechnology Israel Nano NASD

Oct 22, 5:50 PMEnlivex to implement 1-for-16 reverse share split effective October 27, 2026

Peers: LGVN PLUR CELZ BRTX MESO NCEL CELU BCDA LCTX ICU

Index	-
Market Cap	3.43M
Enterprise Value	15.34M
Income	1.24B
Sales	0.00M
Book/sh	231.60
Cash/sh	0.28
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	34
IPO	Jul 31, 2014

P/E	0.00
Forward P/E	-
PEG	-
P/S	-
P/B	0.00
P/C	0.61
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	119.39
Current Ratio	119.39
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	382.12
EPS next Y	-1.15
EPS next Q	-0.28
EPS this Y	-
EPS next Y	-
EPS next 5Y	72.14%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	3852.04%
Sales Y/Y TTM	-
EPS Q/Q	4589.61%
Sales Q/Q	-
Earnings	Aug 24
EPS/Sales Surpr.	0.00% -

Insider Own	89.54%
Insider Trans	0.00%
Inst Own	1.42%
Inst Trans	0.51%
ROA	104.94%
ROE	126.17%
ROIC	31.69%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-42.33%
SMA50	-78.56%
SMA200	-98.10%
Trades

Shs Outstand	16.83M
Shs Float	2.08M
Short Float	4.74%
Short Ratio	0.09
Short Interest	0.10M
52W High	27.15 -99.37%
52W Low	0.19 -10.41%
Volatility	13.09% 16.99%
ATR (14)	0.07
RSI (14)	13.61
Beta	1.54
Rel Volume	2.03
Avg Volume	1.05M
Volume	107,017

Perf Week	-16.00%
Perf Month	-71.57%
Perf Quarter	-95.96%
Perf Half Y	-98.71%
Perf YTD	-98.37%
Perf Year	-98.91%
Perf 3Y	-99.13%
Perf 5Y	-99.86%
Perf 10Y	-99.98%
Recom	1.00
Target Price	80.00
Prev Close	0.20
Price	0.17
Change %	-13.55%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-02-21	Reiterated	H.C. Wainwright	Buy	$22 → $33

Oct-22-26 05:16PM	Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026 (GlobeNewswire) -13.55%
Oct-19-26 08:17AM	Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis (GlobeNewswire)
Sep-22-26 08:00AM	Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens (GlobeNewswire) -6.70%
Jul-30-26 08:00AM	Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June (GlobeNewswire) -13.33%
Jul-29-26 08:00AM	Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones (GlobeNewswire)
08:00AM	Loading…
Jul-28-26 08:00AM	Enlivex Announces $400,000,000 Private Placement (GlobeNewswire) -47.42%
Jul-20-26 08:00AM	Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion (GlobeNewswire)
Jul-13-26 08:00AM	Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra in Age-Related Knee Osteoarthritis (GlobeNewswire)
07:30AM	Exclusive: FDA grants RMAT designation to Enlivexs Allocetra for knee OA (Investing.com)
Jul-07-26 08:00AM	Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026 (GlobeNewswire)
Jun-24-26 08:00AM	Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume (GlobeNewswire)
Jun-22-26 08:45AM	Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion (GlobeNewswire)
Jun-15-26 08:00AM	Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra in Patients with Osteoarthritis (GlobeNewswire)
Jun-02-26 08:00AM	ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026 (GlobeNewswire)
Jun-01-26 08:00AM	Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026 (GlobeNewswire) +6.55%
08:00AM	Loading…
May-28-26 08:00AM	Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board (GlobeNewswire)
May-27-26 08:00AM	Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity (GlobeNewswire) +14.33%
May-18-26 08:00AM	Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis (GlobeNewswire)
May-15-26 04:10PM	Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
May-11-26 01:39PM	Enlivex advances Allocetra while expanding into prediction markets (Proactive)
Apr-30-26 08:30AM	Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange (GlobeNewswire)
Apr-28-26 08:30AM	Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million (GlobeNewswire) -6.38%
Apr-23-26 08:30AM	Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress (GlobeNewswire)
Apr-21-26 08:30AM	Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis (GlobeNewswire)
Apr-08-26 08:30AM	Ondo Global Markets Tokenizes Enlivex's Ordinary Shares (GlobeNewswire) +11.96%
Mar-26-26 08:30AM	Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt (GlobeNewswire) -9.17%
Mar-25-26 08:30AM	Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48 (GlobeNewswire) +9.09%
Mar-24-26 08:30AM	Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program (GlobeNewswire)
Feb-11-26 08:11AM	Enlivex Therapeutics announces new listing of RAIN token on Kraken (TipRanks)
Feb-10-26 08:00AM	Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange (GlobeNewswire)
08:00AM	Loading…
Jan-26-26 08:00AM	Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange (GlobeNewswire) +8.33%
Jan-23-26 08:00AM	Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq (GlobeNewswire)
Jan-14-26 11:46AM	Analyst Sees Massive Upside For Penny Stock Enlivex After RAIN Token Gains Momentum (Benzinga) +9.26%
Jan-07-26 08:00AM	Enlivex Treasury Portfolio Update: Listing of the RAIN Token on KuCoin, a Leading Cryptocurrency Exchange (GlobeNewswire)
Dec-04-25 08:00AM	Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development (GlobeNewswire) +6.42%
Nov-26-25 08:00AM	Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement (GlobeNewswire) -8.16%
Nov-25-25 12:14PM	Nasdaq biotech firm bets $212m on new Arbitrum-based prediction market (DLNews)
Nov-24-25 04:51PM	Enlivex Unveils $212M Rain Token DAT Strategy as RAIN Surges Over 120% (Coinspeaker) +13.74%
10:00AM	Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors (PR Newswire)
08:00AM	Microcap Biotech Firm Raises $212M for Prediction Market Token Treasury Strategy (CoinDesk)
07:55AM	Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board (GlobeNewswire)
07:46AM	EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play (Benzinga)
06:40AM	Enlivex Announces Positive 6-Month Topline Data -Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire)
Oct-28-25 08:15AM	Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025 (GlobeNewswire)
Sep-29-25 08:15AM	D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program (GlobeNewswire)
Sep-11-25 08:00AM	Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra Results (GlobeNewswire) +5.42%
Sep-09-25 08:00AM	Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis (GlobeNewswire)
Aug-19-25 07:53AM	Enlivex advances lead cell therapy to Phase IIb in osteoarthritis (Clinical Trials Arena) -16.00%
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -31.32%
07:45AM	Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis (GlobeNewswire)
Aug-14-25 08:30AM	Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar (GlobeNewswire) +14.10%
Jul-28-25 08:30AM	Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data (GlobeNewswire) +12.30%
Jun-10-25 08:30AM	Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology (GlobeNewswire)
May-20-25 08:00AM	Enlivex Selected to Present at Israeli BioMed 2025 Conference (GlobeNewswire)
Apr-23-25 08:30AM	Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress (GlobeNewswire)
Apr-22-25 06:17AM	Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial (Clinical Trials Arena)
Apr-21-25 08:30AM	Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis (GlobeNewswire)
Apr-03-25 08:00AM	Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis (GlobeNewswire) -6.30%
Mar-17-25 08:00AM	Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis (GlobeNewswire) -5.74%
Mar-04-25 04:30PM	Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra Trial in Knee Osteoarthritis (GlobeNewswire) +5.88%
Mar-03-25 08:22AM	Enlivex Announces Positive Interim Data Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire) -15.00%
Feb-18-25 06:20AM	Enlivex Issues Urgent Statement on Fraudulent News Dissemination (GlobeNewswire)
Feb-11-25 02:30PM	RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis (ACCESSWIRE)
Jan-10-25 09:00AM	Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Dec-12-24 11:29AM	Enlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trial (Clinical Trials Arena)
Dec-11-24 08:30AM	Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis (GlobeNewswire)
Dec-05-24 10:49AM	Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire) -6.15%
Dec-03-24 08:30AM	Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire) +20.37%
Nov-26-24 10:15AM	Join Enlivex Therapeutics' Exclusive Live Investor Webinar and QandA Session on December 3 (ACCESSWIRE)
10:15AM	Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3 (ACCESSWIRE)
Nov-22-24 12:25PM	MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000 (Barrons.com) +10.50%
Nov-20-24 08:00AM	Enlivex Adopts Bitcoin Treasury Reserve Strategy (GlobeNewswire) -5.24%
Nov-14-24 08:00AM	Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis (GlobeNewswire) -8.47%
Nov-12-24 08:00AM	Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire)
Oct-31-24 12:00PM	Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Oct-30-24 08:00AM	Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis (GlobeNewswire)
Sep-26-24 08:30AM	Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire) +8.22%
Sep-24-24 08:30AM	Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire)
Sep-11-24 12:00PM	All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy (Zacks)
Aug-30-24 09:00AM	GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jul-23-24 08:00AM	Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis (GlobeNewswire) +5.11%
Jul-19-24 09:00AM	Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jun-24-24 08:00AM	Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis (GlobeNewswire)
Jun-20-24 08:00AM	Join Enlivex Therapeutics' Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 (GlobeNewswire)
Jun-17-24 08:00AM	Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis (GlobeNewswire)
Jun-03-24 08:00AM	Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis (GlobeNewswire) +8.09%
May-29-24 04:15PM	Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering (GlobeNewswire) -5.07%
May-28-24 08:12AM	Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering (GlobeNewswire)
Apr-29-24 08:00AM	Enlivex CEO Issues Letter to Shareholders Perspectives on Recent Events (GlobeNewswire) +15.28%
Apr-22-24 08:00AM	Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis (GlobeNewswire)
Apr-16-24 07:50AM	Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis (GlobeNewswire) +11.54%
Apr-15-24 01:01PM	Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why (Zacks) -17.72%
Apr-11-24 02:58PM	Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra In Patients with Sepsis (GlobeNewswire) -54.02%
08:05AM	Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis (GlobeNewswire)
Apr-05-24 07:52AM	ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +6.38%
Mar-22-24 10:50AM	Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Feb-26-24 08:30AM	Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis (ACCESSWIRE)
Feb-21-24 08:30AM	Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals (ACCESSWIRE)
Feb-07-24 08:00AM	Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method (GlobeNewswire)
Jan-17-24 08:00AM	Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire)

Show Previous News

Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

Executive ChairmanMr. Shai Novik M.B.A.

Chief Executive OfficerDr. Oren Hershkovitz Ph.D.

Founder & Scientific AdvisorProf. Dror Mevorach M.D.

Chief Financial OfficerMs. Shachar Shlosberger CPA

Chief Operating OfficerDr. Veronique Amor-Baroukh

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENLV

Enlivex Ltd

Upgrade your Finviz experience